乙型肝炎表面抗原与乙型肝炎e抗原定量对核苷类似物治疗慢性乙肝效果的预测  

Evaluation of HBeAg and HBSAg quantification on the therapenutic effect of nucleoside analogues for chronic hepatitis B patients

作　　者：梁家隐[1] 董慧敏[1] 黄凡华 席云[1] LIANG Jia - yin DONG Hui - min HUANG Fan - hua Xi Yun(Clinical Laboratory, the Third Affiliated Hospital of Sun Yat- Sen University, Guangzhou, Guangdong 510630, China)

机构地区：[1]广州市中山大学附属第三医院检验科,广东广州510630

出　　处：《中国卫生检验杂志》2017年第10期1454-1456,共3页Chinese Journal of Health Laboratory Technology

摘　　要：目的监测慢性乙肝(CHB)患者治疗前及治疗中血清HBsAg与HBeAg的浓度变化,评价其与治疗效果的关系。方法分析采用核苷类似物治疗48周的CHB患者HBs Ag、HBeAg基线及用药后24周HBsAg、HBeAg水平变化。结果 HBeAg阴性的CHB患者HBsAg基线中位数为13 228.86 COI,HBeAg阳性CHB患者用药后24周HBeAg水平中位数为237.82 COI,反弹组和持续应答组的差异均有统计学意义(P<0.05)。结论 HBeAg阴性的CHB患者的HBsAg基线及HBeAg阳性CHB患者治疗24周的HBeAg水平,对CHB核苷类似物的治疗效果有预测价值。Objective To investigate the HBeAg and HBsAg concentration change of patients with chronic hepatitis B, so as to evaluate the effect of treatment. Methods Chronic hepatitis B （CHB） were treated with nucleoside analogue for 48 weeks. Ser- um HBsAg and HBeAg baseline levels and after 24 weeks of HBsAg, HBeAg level were quantified. Results HBsAg Baseline （ 13 228.86 COI） in CHB patients with HBeAg negative and HBeAg levels in CHB patients with HBeAg positive（237.82 COI） after 24 weeks treatment rebound and sustained response group were obtained, with the difference statistically significant （P 〈 0.05）. Conclusion HBsAg baseline with HBeAg negative CHB patients and HBeAg levels with HBeAg positive CHB patients for 24 weeks of treatment have predictive value for the ucleoside analogues treatment effect.

关 键 词：慢性乙型肝炎 乙型肝炎表面抗原定量 乙型肝炎e抗原定量 核苷类似物 

分 类 号：R512.62[医药卫生—内科学]